Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients.

The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.


Redwood Pharma Presentations

Aktiespararnas Småbolagsdagen Stockholm
Sheraton Hotel Stockholm
11 June 2018, kl. (TBD)
Sign up here: www.aktiespararna.se (live broadcasting)